| Year |
Citation |
Score |
| 2018 |
Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. The American Journal of Surgical Pathology. PMID 29505425 DOI: 10.1097/Pas.0000000000001042 |
0.324 |
|
| 2017 |
Ahn J, Peng S, Hung CF, Roden RBS, Wu TC, Best SR. Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. The Laryngoscope. PMID 28714529 DOI: 10.1002/Lary.26737 |
0.345 |
|
| 2014 |
Song L, Yang MC, Knoff J, Wu TC, Hung CF. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. Plos One. 9: e115711. PMID 25531529 DOI: 10.1371/journal.pone.0115711 |
0.301 |
|
| 2014 |
Jung ID, Shin SJ, Lee MG, Kang TH, Han HD, Lee SJ, Kim WS, Kim HM, Park WS, Kim HW, Yun CH, Lee EK, Wu TC, Park YM. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. Journal of Immunology (Baltimore, Md. : 1950). 193: 1233-45. PMID 24990079 DOI: 10.4049/jimmunol.1400656 |
0.304 |
|
| 2014 |
Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, Wu TC, Alvarez RD, Roden RB, Hung CF. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell & Bioscience. 4: 11. PMID 24594273 DOI: 10.1186/2045-3701-4-11 |
0.309 |
|
| 2013 |
Gomez BP, Wang C, Viscidi R, Peng S, He L, Wu T-, Hung C. Abstract 478: Strategy to elicit antigen-specific CD8+ T cell -mediated immune responses against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cancer Research. 73: 478-478. DOI: 10.1158/1538-7445.Am2013-478 |
0.367 |
|
| 2013 |
Sandoval F, Nizard M, Terme M, Badoual C, Bureau M, Clement O, Marcheteau E, Gey A, Dransart E, Quintin-Colonna F, Autret G, Wu T, Fridman WH, Johannes L, Tartour E. Abstract 2830: Mucosal imprinting of vaccine induced-CD8+T cells is crucial to inhibit mucosal tumors. Cancer Research. 73: 2830-2830. DOI: 10.1158/1538-7445.Am2013-2830 |
0.406 |
|
| 2012 |
Sandoval F, Terme M, Badoual C, Nizard M, Bureau MF, Freyburger L, Clement O, Gey A, Marcheteau E, Fraisse G, Merillon N, Dransart E, Quintin-Colonna F, Wu T, Fridman WH, et al. Abstract 5388: Local mucosal CD8+T cell response is required to inhibit the growth of orthotopic head and neck and lung cancers Cancer Research. 72: 5388-5388. DOI: 10.1158/1538-7445.Am2012-5388 |
0.426 |
|
| 2011 |
Sen T, Ravi R, Wu T-, Sidransky D, Hoque MO. Abstract 84: OGDHL is epigenetically silenced and suppresses growth in human cervical cancer Cancer Research. 71: 84-84. DOI: 10.1158/1538-7445.Am2011-84 |
0.341 |
|
| 2010 |
Peng S, Monie A, Kang TH, Hung CF, Roden R, Wu TC. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions Gene Therapy. 17: 1453-1464. PMID 20668481 DOI: 10.1038/Gt.2010.106 |
0.373 |
|
| 2009 |
Rowley J, Monie A, Hung CF, Wu TC. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. European Journal of Immunology. 39: 491-506. PMID 19180469 DOI: 10.1002/Eji.200838594 |
0.544 |
|
| 2009 |
Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 361-7. PMID 19118066 DOI: 10.1158/1078-0432.Ccr-08-1725 |
0.36 |
|
| 2008 |
Rowley J, Monie A, Hung CF, Wu TC. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. Journal of Immunology (Baltimore, Md. : 1950). 181: 8237-47. PMID 19050240 DOI: 10.4049/Jimmunol.181.12.8237 |
0.553 |
|
| 2008 |
Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF, Wu TC. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Therapy. 15: 1156-66. PMID 18401437 DOI: 10.1038/Gt.2008.53 |
0.393 |
|
| 2008 |
Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 107: 198-217. PMID 18400605 DOI: 10.1016/S0929-6646(08)60138-2 |
0.338 |
|
| 2008 |
Roden RBS, Monie A, Wu T-. Human papillomavirus vaccine for cervical cancer prevention Hot Topics in Oncology. DOI: 10.4147/Hto-080307 |
0.341 |
|
| 2008 |
Trimble C, Peng S, Roden R, Gravitt P, Pardoll D, Sugar E, Thoburn C, Wu T. OR.52. Phase I Evaluation of Therapeutic, E7-targeted DNA Vaccination in Women with HPV16+ High Grade Cervical Dysplasia (CIN2/3) Clinical Immunology. 127: S22. DOI: 10.1016/J.Clim.2008.03.058 |
0.33 |
|
| 2007 |
Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Research. 67: 1832-41. PMID 17308126 DOI: 10.1158/0008-5472.Can-06-3014 |
0.502 |
|
| 2006 |
Roden R, Wu T-. How will HPV vaccines affect cervical cancer Nature Reviews Cancer. 6: 753-763. PMID 16990853 DOI: 10.1038/Nrc1973 |
0.35 |
|
| 2005 |
Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC, Hung CF. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Therapy. 12: 1180-6. PMID 15800656 DOI: 10.1038/Sj.Gt.3302519 |
0.356 |
|
| 2004 |
Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell. 5: 533-8. PMID 15193256 DOI: 10.1016/J.Ccr.2004.05.029 |
0.338 |
|
| 2003 |
Devaraj K, Gillison ML, Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Critical Reviews in Oral Biology and Medicine : An Official Publication of the American Association of Oral Biologists. 14: 345-62. PMID 14530303 DOI: 10.1177/154411130301400505 |
0.358 |
|
| 2002 |
Ling M, Wu T-. Cancer Treatment Combining Tumor-Specific Immunotherapy and Anti-Angiogenesis in a DNA Vaccine Directions in Science. 1: 57-59. DOI: 10.1100/Tsw.2002.212 |
0.338 |
|
| 2001 |
Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. Journal of Immunology (Baltimore, Md. : 1950). 167: 6471-9. PMID 11714814 DOI: 10.4049/Jimmunol.167.11.6471 |
0.383 |
|
| 2001 |
Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site Journal of Virology. 75: 9654-9664. PMID 11559797 DOI: 10.1128/Jvi.75.20.9654-9664.2001 |
0.384 |
|
| 2001 |
Hung C, Cheng W, Chai C, Hsu K, He L, Ling M, Wu T-. Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen Journal of Immunology. 166: 5733-5740. PMID 11313416 DOI: 10.4049/Jimmunol.166.9.5733 |
0.341 |
|
| 2001 |
Cheng W, Hung C, Hsu K, Chai C, He L, Ling M, Slater LA, Roden RBS, Wu T-. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Human Gene Therapy. 12: 235-252. PMID 11177561 DOI: 10.1089/10430340150218387 |
0.32 |
|
| 2001 |
Cheng W, Hung C, Chai C, Hsu K, He L, Ling M, Wu T-. Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen Journal of Virology. 75: 2368-2376. PMID 11160740 DOI: 10.1128/Jvi.75.5.2368-2376.2001 |
0.32 |
|
| 2000 |
Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress & Chaperones. 5: 401-5. PMID 11189443 DOI: 10.1379/1466-1268(2000)005<0401:Ioahpt>2.0.Co;2 |
0.403 |
|
| 2000 |
Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clinical and Experimental Immunology. 121: 216-25. PMID 10931134 DOI: 10.1046/J.1365-2249.2000.01293.X |
0.385 |
|
| 1995 |
Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proceedings of the National Academy of Sciences of the United States of America. 92: 11671-5. PMID 8524826 DOI: 10.1073/Pnas.92.25.11671 |
0.338 |
|
| 1995 |
Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, Greer CE, You SL, Huang TW, Wu TC, O'Leary TJ, Seidman JD, Blot WJ, Meinert CL, Manos MM. Human papillomavirus and cervical neoplasia: A case-control study in Taiwan International Journal of Cancer. 62: 565-571. PMID 7665227 DOI: 10.1002/Ijc.2910620513 |
0.304 |
|
| 1986 |
McDonnell JM, McDonnell PJ, Mounts P, Wu TC, Green WR. Demonstration of papillomavirus capsid antigen in human conjunctival neoplasia. Archives of Ophthalmology (Chicago, Ill. : 1960). 104: 1801-5. PMID 3024607 DOI: 10.1001/Archopht.1986.01050240075043 |
0.313 |
|
| Show low-probability matches. |